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Abstruct 
Heparin is widely used as anticoagulant for prophJ'.laxis of thromboembolism, in extra-
corporeal circulation, angiography etc. Since the measurement of heparin concentration in 
whole blood is difficult and its effect depends on individuals, determination of appropriate 
heparin dose during cardiopulmonary bypass is not easy. For solution of these problems, 
we introduced activated coagulation time (ACT) which is reported by Hattersley in 1966. 
ACT is measured after mixing diatomite with whole blood and is obtained more rapidly 
than Lee-White coagulation time. In this study, Hemochron 800, an automated instrument 
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for detecting blood coagulation, was used. ACT obtain巴d by Hernochron 800 is called 
Hernochron Time. 
The study group consists of 30 patients who underwent open-heart surgery or received 
heparin therapy. Hemochron Time of non-heparinized blood ranged from 103 to 142 
seconds and those of the heparinized blood ranged from 246 to 343 seconds. Before 
cardiopulmonary bypass, 3mg per kilogram body weight of heparin was administered 
intravenously, and lOmg per 200ml of ACD stored blood or 500ml of plasma expander was 
added in bypass circuit. Heparin was administered so as to control Hemochron Time 
between 300 and 400 seconds. At the end of bypass, Hemochron Time was also used as 
indicator for determining protamine dose. 
Under heparin therapies which were performed after reconstructive surgery of perip-
heral arteries, Hemochron Time ranged from 130 to 182 seconds. 
After introduction of this method, the amount of heparin and protamine used were 
decreased. We found Hemochron Time to be helpful for the management of heparinization 




































して珪藻土 ( diatomaceous earth, Ce lite-John-




















































In vitro における抗凝固能測定は， invivoの血中
へパリン濃度を推定するために新鮮静脈血及ぴACD
保存血を用い，プラスチック試験管内で，血液4ml
あたり 0.05～0.15mgのへパリ ンと， ACD血には充
分量のカルチコールを加えて，同様にヘモクロンタイ
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Fig. 7. Comparison of Hemochron Time between adult and 
child in open-heart surgery 
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秒に短縮した.l.5mg/kg, 2mg/kg, 4mg /kgのプロ
タミ ン投与でそれぞれ， 127.3土1.89秒， l'.:2.7土12.21
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